Source comparison
TB-500 Research Protocols: Comparison Across Delivery Methods
Subcutaneous Injection 2–6mg per dose Peak plasma: 20–30 min Refrigerate 2–8°C, use within 28 days Gold standard for systemic delivery. Consistent absorption, minimal equipment Intramuscular Injection Peak plasma: 15–25 min Faster uptake than subcutaneous; hig
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- 2–6mg per dose
- Peak plasma: 20–30 min
- Refrigerate 2–8°C, use within 28 days
- Gold standard for systemic delivery. Consistent absorption, minimal equipment
- Intramuscular Injection
- Peak plasma: 15–25 min
- Faster uptake than subcutaneous; higher risk of injection site inflammation
- Intravenous Infusion
- 1–4mg per dose
- Immediate bioavailability
- Required for acute cardiovascular models; bolus delivery risks hypotension
- Intraperitoneal Injection
- 3–8mg per dose
- Peak plasma: 45–60 min
- Acceptable for rodent systemic studies; variable absorption depending on peritoneal inflammation
- Topical Application
- Not established
- Minimal systemic absorption
- N/A
- Poor penetration through intact skin; reserved for localised wound models with barrier disruption
- Delivery method selection depends on study design. Subcutaneous remains the most reproducible for longitudinal studies; intraperitoneal is practical for high-throughput rodent screening but introduces absorption variability.